The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer

被引：0
|
作者：
Kluemper, Niklas [1 ,2 ,3 ]
Eckstein, Markus [4 ,5 ,6 ]
机构：
[1] Univ Hosp Bonn, Dept Urol, Bonn, Germany
[2] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldor, Bonn, Germany
[3] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
[4] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany
[5] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, EMN Comprehens Canc Ctr, Erlangen, Germany
[6] Bavarian Ctr Canc Res, Munich, Germany
来源：
EUROPEAN UROLOGY | 2025年 / 87卷 / 01期
关键词：
D O I：
10.1016/j.eururo.2024.09.019
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e17 / e18
页数：2
相关论文
共 50 条
  • [21] DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer
    Lu, Eric
    Thomas, George V.
    Chen, Yiyi
    Wyatt, Alexander W.
    Lloyd, Paul
    Youngren, Jack
    Quigley, David
    Bergan, Raymond
    Bailey, Shawna
    Beer, Tomasz M.
    Feng, Felix Y.
    Small, Eric J.
    Alumkal, Joshi J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (08): : 933 - 937
  • [22] Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
    Ye, Senlin
    Wang, Haohui
    He, Kancheng
    Peng, Mou
    Wang, Yinhuai
    Li, Yuanwei
    Jiang, Shusuan
    Li, Jin
    Yi, Lu
    Cui, Rongrong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA
    Li, Chennan
    Baj, Anna
    Seo, Clara C. Y.
    Terrigino, Nicholas T.
    Bright, John R.
    Hennigan, S. Thomas
    King, Isaiah M.
    Wilkinson, Scott
    Trostel, Shana Y.
    Figg, William D.
    Dahut, William L.
    Lee, Jung Min
    Takeda, David Y.
    Karzai, Fatima
    Sowalsky, Adam G.
    CANCER RESEARCH, 2024, 84 (03)
  • [24] Testosterone defining prognosis and predicting response in castration-resistant prostate cancer (CRPC)
    Gomez de Liano, A.
    Reig, O.
    Mellado, B.
    Martin, C.
    Sancho, G.
    Palou, J.
    Anguera, G.
    Arqueros, C.
    Condori, D.
    Maroto-Rey, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S702 - S702
  • [25] Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer.
    Hwang, Jihyun
    Kwon, Woo Sun
    Park, Juin
    Bae, Hyun Joo
    Jeong, Inhye
    Kang, Sun Kyoung
    Kim, Tae Soo
    Che, Jingmin
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2021, 81 (13)
  • [26] Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Pond, Gregory Russell
    Nagy, Rebecca J.
    Nussenzveig, Roberto H.
    Hahn, Andrew W.
    Sartor, Oliver
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    Ledet, Elisa M.
    Naik, Gurudatta
    Armstrong, Andrew J.
    Wang, Jue
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Grivas, Petros
    Pal, Sumanta K.
    Lanman, Richard B.
    Talasaz, AmirAli
    Lilly, Michael B.
    CANCER, 2019, 125 (09) : 1459 - 1469
  • [27] DNA repair genes aberrations in germline DNA in metastatic castration-resistant prostate cancer patients
    Mateo, Joaquin
    Carreira, Suzanne
    Mossop, Helen
    Rescigno, Pasquale
    Kolinsky, Michael
    Castro, Elena
    Balasopoulou, Ada
    Hunt, Jo
    Roda, Desamparados
    Bertan, Claudia
    Goodall, Jane
    Miranda, Susana
    Flohr, Penny
    Porta, Nuria
    Kote-Jarai, Zsofia
    Olmos, David
    Lord, Christopher J.
    Hall, Emma
    Eeles, Ros
    de Bono, Johann S.
    CANCER RESEARCH, 2016, 76
  • [28] Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
    De Laere, B.
    Crippa, A.
    Ghysel, C.
    Ost, P.
    Rajan, P.
    Eklund, M.
    Dirix, L.
    Gronberg, H.
    Lindberg, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Role of the Tumor Suppressor RB in the Development of Localized and Castration-Resistant Prostate Cancer
    Ryabov V.M.
    Voskresenskiy M.A.
    Popov B.V.
    Cell and Tissue Biology, 2022, 16 (5) : 434 - 441
  • [30] Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
    Velho, Pedro Isaacsson
    Bastos, Diogo Assed
    Saint'ana, Pedro Tofani
    Rigatti, Brenda
    da Costa, Emily Tonin
    Muniz, David Q. B.
    Andreis, Felipe
    Ferreira, Rafael Dal Ponte
    Pedrotti, Luana Giongo
    Maistro, Simone
    Katayama, Maria Lucia Hirata
    Folgueira, Maria Aparecida Azevedo Koike
    Morelle, Alessandra
    Leal, Alessandro
    de Castro, Gilberto
    CLINICAL CANCER RESEARCH, 2024, 30 (23) : 5342 - 5352
12345